Angiotensin receptor blocker (ARB) valsartan has been found to be having its use in subjects with impaired glucose metabolism, there by reducing incidence of onset of diabetes. Here is a study.

Team@CMHF

Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB) valsartan for 5 years resulted in a relative reduction of 14% in the incidence of type 2 diabetes in subjects with impaired glucose metabolism (IGM).

Investigation was done to see whether improvements in β-cell function and/or insulin sensitivity underlie these preventive effects of the ARB valsartan in the onset of type 2 diabetes.

Valsartan increased first-phase and second-phase glucose-stimulated insulin secretion compared with placebo. In addition, valsartan increased the OGTT-derived insulinogenic index. Valsartan treatment significantly decreased systolic and diastolic blood pressure compared with placebo (P<0.001).

BMI remained unchanged in both treatment groups (P = 0.89).

CONCLUSIONS Twenty-six weeks of valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM. These findings may partly explain the beneficial effects of valsartan in the reduced incidence of type 2 diabetes.

Ref: http://www.docguide.com/valsartan-improves-beta-cell-function-and-insulin-sensitivity-subjects-impaired-glucose-metabolism-r?hash=80445d1a&eid=18580&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2